- About ERC
- Projects & figures
- News & Events
- Managing your project
For the first time ever, two ERC grantees, Prof. Luca G. Guidotti and Dr Matteo Iannacone, have observed in vivo how specific white blood cells, so-called cytotoxic T lymphocytes, identify, target and attack liver cells that are infected with the hepatitis B virus. To witness these immune cells in action in real time, the two scientists developed advanced, dynamic imaging techniques. An estimated 240 million people are chronically infected with hepatitis B worldwide. This discovery, published today in the scientific journal Cell, opens new horizons for the development of novel therapies.
Vaccination has achieved huge success in controlling many devastating infectious diseases. However, there are still many such diseases, or ‘pathogens’, against which we cannot generate life-long protective immunity. On the eve of Croatia’s accession to the EU, Professor Stipan Jonjic’s ERC-funded research into new vaccines to offer better protection– is already underway. Prof Jonjic is the first Croatian ERC grantee to base his project in Croatia.
Cancer treatment and cure remains one of the main challenges of modern medicine, with more than 12 million people around the world diagnosed every year. ERC funded research, which has already shown initial positive results, proposes a new approach to define the role of stem cells in the onset and development of skin cancer. This innovative method could potentially lead to a drug that may stop the growth of skin cancer.